Effect of interleukin-2 on the manifestation and growth of acetoxymethyl-methylnitrosamine-induced colorectal rat adenocarcinoma.
The effect of highly purified human interleukin-2 (IL-2) was assessed on acetoxymethyl-methylnitrosamine(AMMN)-induced colorectal Sprague-Dawley rat adenocarcinoma. Treatment was given for 5 weeks and started 5 weeks after a period of 10 weeks intrarectal administration of 2 mg/kg of AMMN once a week. Animals which showed no evidence of tumors by endoscopical examination of the gut were given 10,000 units/kg of IL-2 s.c. into the dorsal region 5 days a week. Blood samples were analyzed from half of the animals before and 72 h after the end of the treatment. The median tumor volume and the median tumor number per rat were lower in the treated group than in the control. A significant decrease in response to two mitogens (PHA, Con-A) was seen in tumor-bearing rats concomitantly with the tumor growth. The immunological suppression was not restored by treatment with IL-2. No differences in natural killer activity or interferon levels were detected between the control and the treated group. These data indicate some antitumor effect of IL-2 given before the manifestation of tumors in AMMN-induced colorectal rat adenocarcinoma.
D000230:Adenocarcinoma / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D000818:Animals; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D004128:Dimethylnitrosamine / Q000031:analogs & derivatives; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008297:Male; D051381:Rats; D012004:Rectal Neoplasms / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*
D007376:Interleukin-2; C014659:methyl(acetoxymethyl)nitrosamine; D004128:Dimethylnitrosamine